Subscribe
2 June 2025NewsAmericasMarisa Woutersen

Honigman lands two leading litigators in Chicago office

The seasoned patent litigators join from Mayer Brown, bringing decades of high-stakes experience in pharma and biotech patent disputes, including work on Hatch-Waxman and biosimilar litigation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Careers
Baker McKenzie adds London partner with ‘enviable’ expertise
27 May 2025   New hire is a specialist in pharmaceutical regulatory matters, complex patent disputes, and cross-border transactional support for biotech.
Careers
Taylor Wessing expands in Europe with Paris team
7 May 2025   Pinsent Masons’ head of IP moves with a small team that will be bolstered by an A&O Shearman associate.
Americas
Foley adds five-partner team from Perkins Coie and K&L Gates
6 May 2025   The team brings experience in Section 337 investigations, post-grant proceedings, and complex patent litigation in biopharmaceutical and medical device sectors.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations
UK gets new IP minister following cabinet reshuffle
Barnes & Thornburg reveals five new IP leaders